Last reviewed · How we verify

Pyridinylmethyl-14C-labeled isavuconazonium sulfate

Astellas Pharma Global Development, Inc. · Phase 1 active Small molecule

Pyridinylmethyl-14C-labeled isavuconazonium sulfate is a Small molecule drug developed by Astellas Pharma Global Development, Inc.. It is currently in Phase 1 development. Also known as: BAL8557.

At a glance

Generic namePyridinylmethyl-14C-labeled isavuconazonium sulfate
Also known asBAL8557
SponsorAstellas Pharma Global Development, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pyridinylmethyl-14C-labeled isavuconazonium sulfate

What is Pyridinylmethyl-14C-labeled isavuconazonium sulfate?

Pyridinylmethyl-14C-labeled isavuconazonium sulfate is a Small molecule drug developed by Astellas Pharma Global Development, Inc..

Who makes Pyridinylmethyl-14C-labeled isavuconazonium sulfate?

Pyridinylmethyl-14C-labeled isavuconazonium sulfate is developed by Astellas Pharma Global Development, Inc. (see full Astellas Pharma Global Development, Inc. pipeline at /company/astellas-pharma-global-development-inc).

Is Pyridinylmethyl-14C-labeled isavuconazonium sulfate also known as anything else?

Pyridinylmethyl-14C-labeled isavuconazonium sulfate is also known as BAL8557.

What development phase is Pyridinylmethyl-14C-labeled isavuconazonium sulfate in?

Pyridinylmethyl-14C-labeled isavuconazonium sulfate is in Phase 1.

Related